沙罗格列扎和肉豆蔻酸用于治疗局灶性节段性肾小球硬化(FSGS).pdf,本发明涉及一种包含沙罗格列扎和肉豆蔻酸或其盐或溶剂化物的药物制剂,其用于治疗局灶性节段性肾小球硬化(FSGS)。(19)国家知识产权局 (12)发明专利申请 (10)申请公布号 CN 116600802 A (43)申请公布日 2023.0
3. Stokes MB, Markowitz GS, Lin J, et al. Glomerular tip lesion: a distinct entity within the minimal change disease/focal segmental glomerulosclerosis spectrum. Kidney Int 2004; 65:1690. 4. Thomas DB, Franceschini N, Hogan SL, et al. Clinical and pathologic characteristics of focal segmental...
Focal and segmental glomerulosclerosis (FSGS) is the most common glomerular cause of end-stage kidney disease (ESKD). Although the etiology of FSGS has not been fully elucidated, recent results from the positional cloning of genes mutated in nephrotic syndromes are now beginning to provide insight ...
GLOMERULAR-DISEASEOUTCOMESCHILDRENIntroductionFocal segmental glomerulosclerosis (FSGS) is a leading cause of kidney disease and can progress to end stage kidney disease (ESKD). An overview of symptoms and impacts of the disease experienced will help inform the selection or development of fit-for-...
Focal and segmental glomerulosclerosis (FSGS) is the most common glomerular cause of end-stage kidney disease (ESKD). Although the etiology of FSGS has not been fully elucidated, recent results from the positional cloning of genes mutated in nephrotic syndromes are now beginning to provide insight ...
Purpose: Idiopathic focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) are chronic glomerulopathies which may compromise patients' quality of life, and for which there is no cure. This literature review aimed to summarize our current understanding of the pathophysiology, ...